Stay updated on Cisplatin, Romidepsin & Nivolumab in TNBC Clinical Trial

Sign up to get notified when there's something new on the Cisplatin, Romidepsin & Nivolumab in TNBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cisplatin, Romidepsin & Nivolumab in TNBC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a significant update in the study details regarding the combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer or BRCA mutation-associated locally recurrent or metastatic breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:47:08.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes a detailed explanation of eligibility criteria and examples, as well as specific inclusion and exclusion criteria for the study.
    Difference
    47%
    Check dated 2024-05-22T21:25:16.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:15:21.000Z thumbnail image

Stay in the know with updates to Cisplatin, Romidepsin & Nivolumab in TNBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cisplatin, Romidepsin & Nivolumab in TNBC Clinical Trial page.